The combination therapy group was more effective in suppressing the progression and metastasis of tumor than either galunisertib or anti‐PD‐L1 monotherapy and had better survival rates (Figure 8B–E,H–K; Figure S18A–D, Supporting Information). This evidence concerns the gene CD274 and neoplasm.